PRIMALS is a robust precision medicine program to promote neurodegeneration patho-mechanisms and boost clinical research. PRIMALS endpoints are the discovery and substantiated validation of precision biomarkers for amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease). The program builds on research in human models of disease based on stem cell and then in human patient blood samples. The researchers expect disease-specific results and conceptual breakthroughs that can be extended to other pathologies.